The mechanisms by which KRAS and BRAF oncogenes are involved in early-stage cancer development are beginning to be unravelled by analysis of genetically engineered mouse (GEM) models developing autochthonous tumours, especially for cancer types in which premalignant precursor lesions are difficult to access in humans. Here, KRAS is linked to cancer.